97 related articles for article (PubMed ID: 23207411)
41. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
[TBL] [Abstract][Full Text] [Related]
42. Assaying phenothiazine derivatives as trypanothione reductase and glutathione reductase inhibitors by theoretical docking and molecular dynamics studies.
Iribarne F; Paulino M; Aguilera S; Tapia O
J Mol Graph Model; 2009 Nov; 28(4):371-81. PubMed ID: 19801198
[TBL] [Abstract][Full Text] [Related]
43. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
[TBL] [Abstract][Full Text] [Related]
44. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.
Equbal T; Silakari O; Rambabu G; Ravikumar M
Bioorg Med Chem Lett; 2007 Mar; 17(6):1594-600. PubMed ID: 17236767
[TBL] [Abstract][Full Text] [Related]
45. Towards the synthesis of bisubstrate inhibitors of protein farnesyltransferase: Synthesis and biological evaluation of new farnesylpyrophosphate analogues.
Duez S; Coudray L; Mouray E; Grellier P; Dubois J
Bioorg Med Chem; 2010 Jan; 18(2):543-56. PubMed ID: 20036564
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.
Li Q; Woods KW; Wang W; Lin NH; Claiborne A; Gu WZ; Cohen J; Stoll VS; Hutchins C; Frost D; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2005 Apr; 15(8):2033-9. PubMed ID: 15808463
[TBL] [Abstract][Full Text] [Related]
47. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
Mitsch A; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
[TBL] [Abstract][Full Text] [Related]
48. New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
Andrzejak V; Muccioli GG; Body-Malapel M; El Bakali J; Djouina M; Renault N; Chavatte P; Desreumaux P; Lambert DM; Millet R
Bioorg Med Chem; 2011 Jun; 19(12):3777-86. PubMed ID: 21612933
[TBL] [Abstract][Full Text] [Related]
49. Surfing the piperazine core of tricyclic farnesyltransferase inhibitors.
Rokosz LL; Huang CY; Reader JC; Stauffer TM; Chelsky D; Sigal NH; Ganguly AK; Baldwin JJ
Bioorg Med Chem Lett; 2005 Dec; 15(24):5537-43. PubMed ID: 16202593
[TBL] [Abstract][Full Text] [Related]
50. Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
Wlodarczyk N; Le Broc-Ryckewaert D; Gilleron P; Lemoine A; Farce A; Chavatte P; Dubois J; Pommery N; Hénichart JP; Furman C; Millet R
J Med Chem; 2011 Mar; 54(5):1178-90. PubMed ID: 21299244
[TBL] [Abstract][Full Text] [Related]
51. 7-imidazolylalkanamido-1-carboxylalkylbenzo-diazepine, a novel series of farnesyltransferase inhibitors.
Wan SB; Chu FM; Guo ZR
Yao Xue Xue Bao; 2002 Jul; 37(7):516-21. PubMed ID: 12914320
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
[TBL] [Abstract][Full Text] [Related]
53. Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors.
Liu XH; Jia YM; Song BA; Pang ZX; Yang S
Bioorg Med Chem Lett; 2013 Feb; 23(3):720-3. PubMed ID: 23265905
[TBL] [Abstract][Full Text] [Related]
54. Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.
Bolchi C; Pallavicini M; Bernini SK; Chiodini G; Corsini A; Ferri N; Fumagalli L; Straniero V; Valoti E
Bioorg Med Chem Lett; 2011 Sep; 21(18):5408-12. PubMed ID: 21802946
[TBL] [Abstract][Full Text] [Related]
55. Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.
Cabeza M; Zambrano A; Heuze I; Carrizales E; Palacios A; Segura T; Valencia N; Bratoeff E
Steroids; 2009 Oct; 74(10-11):793-802. PubMed ID: 19406144
[TBL] [Abstract][Full Text] [Related]
56. Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements.
Sakowski J; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2002 Apr; 335(4):135-42. PubMed ID: 12112033
[TBL] [Abstract][Full Text] [Related]
57. Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase.
Schlauderer F; Lammens K; Nagel D; Vincendeau M; Eitelhuber AC; Verhelst SH; Kling D; Chrusciel A; Ruland J; Krappmann D; Hopfner KP
Angew Chem Int Ed Engl; 2013 Sep; 52(39):10384-7. PubMed ID: 23946259
[No Abstract] [Full Text] [Related]
58. Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
Ellis CD; Oppong KA; Laufersweiler MC; O'Neil SV; Soper DL; Wang Y; Wos JA; Fancher AN; Lu W; Suchanek MK; Wang RL; De B; Demuth TP
Bioorg Med Chem Lett; 2006 Sep; 16(18):4728-32. PubMed ID: 16870441
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and evaluation of malonate-based inhibitors of phosphosugar-metabolizing enzymes: class II fructose-1,6-bis-phosphate aldolases, type I phosphomannose isomerase, and phosphoglucose isomerase.
Desvergnes S; Courtiol-Legourd S; Daher R; Dabrowski M; Salmon L; Therisod M
Bioorg Med Chem; 2012 Feb; 20(4):1511-20. PubMed ID: 22269276
[TBL] [Abstract][Full Text] [Related]
60. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
Lu A; Zhang J; Yin X; Luo X; Jiang H
Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
